SNBL USA, an Everett, Wash.-based, wholly owned subsidiary of Shin Nippon Biomedical Laboratories, has received a formal close out letter from the FDA indicating that it has successfully resolved all the issues identified in an August 10, 2010, warning letter.
Accelovance has named Stephan A. Bart Sr., M.D. chief medical officer. Bart will be responsible for medical affairs and site operations, focused on enhancing the level of clinical solutions Accelovance can provide to clients.
SNBL USA has named Mark T. Crane vice president of business development. Crane will have overall responsibility for the company’s marketing, sales and business development efforts and will be tasked with driving the growth of SNBL USA’s business model and fostering positive relationships with new and current customers.